tbuckley/cabot-search huggingface dataset:
FRI0612-HPR The Development of Physiotherapy-Led Musculoskeletal Triage Services in Ireland
Authors: A. Brennan, R. Breen, J. Ashton, C. Edel, C. Farrell, D. Moore, P. Kenny, O. FitzGerald
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In 2012, funding was approved for twenty-four Advanced Practice Physiotherapy (APP) posts in Ireland through the Clinical Strategy and Programmes Directorate of the HSE. These posts were to provide orthopaedic and rheumatology triage clinics across 16 hospitals throughout the country. <h3>Objectives</h3> The aims of these clinics were to reduce the waiting time for outpatient consultation for orthopaedic and rheumatology patients; to establish a diagnosis and triage patients along the most appropriate care pathway according to their diagnosis. <h3>Methods</h3> Initially 18 APPs were recruited in 2012 and currently there are 22.5 in post nationally. Guidelines regarding inclusion for attendance at these clinics were disseminated to APPs recruited to posts. Clinical governance for APP clinics is provided by either a consultant orthopaedic surgeon or a consultant rheumatologist who provide support with clinical diagnosis; with the ordering of investigations and with management of patients as appropriate. <h3>Results</h3> From January 2012 to May 2015 48,279 patients have been removed from orthopaedic and rheumatology waiting lists nationally. In orthopaedic clinics APPs reviewed 33,092 new patients and discharged 25,917 (78%); in rheumatology clinics APP9s reviewed 7,550 new patients and of this 5,417 (72%) were discharged following their review. <h3>Conclusions</h3> Advanced Practice Physiotherapist9s can assist in the management of orthopaedic and rheumatology waiting lists. These services provide patients with early access for a specialist opinion and management and therefore prevent chronicity of symptoms. It can be hypothesized that prevention of chronicity would result in a reduction in the use of health care resources by this subgroup of patients. <h3>Disclosure of Interest</h3> None declared
AB0682 Correlation between Disease Activity and Cardiovascular Parameters in Patients with Ankylosing Spondylitis
Authors: F. Atzeni, L. Gianturco, S. Bongiovanni, R. Talotta, P. Sarzi-Puttini, M. Turiel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> As cardiovascular (CV) involvement is frequent in patients with rheumatic diseases, it is important to implement strategies of early diagnosis, treatment and follow-up and to understand the relationship between this complication and disease activity. <h3>Objectives</h3> To investigate the correlations between the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and a series of conventional and unconventional CV markers in a group of patients with ankylosing spondylitis (AS). <h3>Methods</h3> We studied 30 patients with AS diagnosed using the New York criteria (14 males and 16 females with a mean age of 53.07±10.73 years), all of whom underwent a standard echocardiographic examination, a carotid ultrasound study (including IMT and PWV assessment), and speckle tracking echocardiography (STE). <h3>Results</h3> Our AS patients had impaired STE-measured LV myocardial longitudinal ɛ(median 19.83%, IQR 16.00–24.40% <i>vs</i> 21.46%, IQR 18.35–25.69%; <i>p</i>&lt;0.05) and higher PWV (right: median 7.81 m/sec, IQR 7.03–8.45 m/sec <i>vs</i> 6.86 m/sec, IQR 6.42–7.99 m/sec; <i>p</i>=0.07: left: median 7.77 m/sec, IQR 6.97–8.38 m/sec <i>vs</i> 6.85 m/sec, IQR 6.28–7.88 m/sec; <i>p</i>=0.06) compared to healthy controls. Stepwise regression analysis revealed a weak correlation between BASDAI values and right (p=0.04) and left carotid PWV (p=0.05), whereas LV global longitudinal strain (GLS) assessed by means of STE very significantly correlated with disease activity (p=0.001). There was no correlation with common carotid IMT (cIMT) or ejection fraction (EF). <h3>Conclusions</h3> PWV and (especially) GLS are very important markers of CV damage and may identify CV involvement in AS patients earlier than conventional indices such as EF or cIMT, furthermore the are a correlation between these markers and disease activity. However, these findings need to be confirmed in a larger series of patients. <h3>Disclosure of Interest</h3> None declared
ATPS-34THE ROLE OF Lrig1 AND Lrig3 IN PDGF-INDUCED EXPERIMENTAL GLIOMA
Authors: Camilla Holmlund, Feng Mao, Thais Langer Jacobus, Wanzhong Wang, Roger Henriksson, Håkan Hedman
Journal: Neuro-Oncology (2015)

In both adult glioblastoma (GBM) and pediatric diffuse intrinsic pontine glioma (DIPG) dysregulated platelet-derived growth factor (PDGF) receptor (PDGFR) signaling is a common feature. The majority of GBMs of the pro-neural subtype and many DIPGs have activating mutations, or amplifications, of PDGFRA gene and it was recently suggested that PDGFA drives the initiation of all non-CIMP GBMs. Leucine-rich repeats and immunoglobulin-like domains (Lrig) -1 is a negative regulator of PDGFRA and a tumor suppressor in the mouse intestines. The functions of Lrig2 and Lrig3 are less well defined. However, recently we showed that Lrig2-deficient mice are protected against PDGF-induced glioma. The roles of Lrig1 and Lrig3 in PDGF-induced glioma have not been addressed, previously. In the present study, brain tumors were induced in Ntv-a transgenic mice of different Lrig1 and Lrig3 genotypes by intracranial injection with PDGFB-encoding RCAS-producing DF-1 cells. Lrig1-deficient mice developed more tumors than wild-type mice (36%, n = 44 vs. 22%, n = 36). Furthermore, Lrig1-deficient mice developed more high grade tumors than the corresponding wild-type mice (11% vs. 2%). Lrig3-deficient mice, in contrast, developed fewer tumors than the corresponding wild-type mice (64%, n = 26 vs. 77%, n = 30). Additionally, Lrig3-deficient mice developed no tumor of high grade, whereas 13% of the corresponding wild-type mice developed high grade tumors. In situ hybridization analysis revealed Lrig3 expression within the induced wild-type tumors; Lrig1 expression has not been analyzed, yet. Thus, this study revealed an apparent glioma-protective function of Lrig1, and an apparent glioma-promoting function of Lrig3, in PDGFB-induced glioma. These results suggest that Lrig1 and Lrig3 might have opposing functions in gliomagenesis.
Knowing When and How to Use Medical Products
Authors: Robert M. Califf, Rachel E. Sherman, Andrew Slavitt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry.
Authors: Tiziana Grafone, Michela Palmisano, Emanuela Ottaviani, Alberto Maria Martelli, Alessandra Cappellini, Matilde Follo, Nicoletta Testoni, Stefania Paolini, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2006)
WT1-Specific Immune Responses in Patients with High-Risk Multiple Myeloma Undergoing Allogeneic T Cell-Depleted Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions
Authors: Eleanor Tyler, Achim A Jungbluth, Richard J. O'Reilly, Guenther Koehne
Journal: Blood (2011)
Bone-to-Bone Stem Cell Infusion In Graft Failure After Haploidentical Hematopoietic Stem Cell Transplantation: Safety and Feasibility. Three Case Report
Authors: Fabio Giglio, Simona Malato, Daniela Clerici, Carlo Messina, Sara Mastaglio, Simone Claudiani, Bernhard Gentner, Matilde Zambelli, Andrea Assanelli, Vincenzo Matozzo, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri
Journal: Blood (2010)
FLT3-ITDs Introduce a Myeloid Differentiation and Transformation Bias to Multipotent Lympho-Myeloid Progenitors
Authors: Adam J. Mead, Shabnam Kharazi, Iain C Macaulay, Debbie Atkinson, Stephen Loughran, Michael Lutteropp, Petter Woll, Sidinh Luc, Natalija Buza-Vidas, Helen Ferry, Claus Nerlov, Ewa Sitnicka, Sten Eirik W. Jacobsen
Journal: Blood (2011)
Establishment and Characterization of a tel/abl Rearrangement Responsible for Imatinib Sensitivity in bcr/abl Negative Acute Lymphoblastic Leukemia.
Authors: Jörg Bäumler, J.H. Frederik Falkenburg, Marianke L.J. van Schie, Karoly Szuhai, Martine Pape, Sina Droll, Oliver G. Ottmann, Bart Nijmeijer
Journal: Blood (2007)
First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).
Authors: Konstantinos Anargyrou, Theodoros P. Vassilakopoulos, Konstantinos Tsionos, Panayiotis Kokkoris, Georgios Boutsikas, Maria K. Angelopoulou, Dimitrios Christoulas, Stavroula Masouridou, Maria Dimou, Athanasios Papatheodorou, Panayiotis Panayiotidis, Evangelos Terpos
Journal: Blood (2009)
Alemtuzumab induction allows better rejection free graft survival incomparison to basiliximab albeit increased post transplant viralinfections
Authors: V. Siddagangaiah, H. Sharma, N. Lal, J. Rai, M. Howse, D. Ridgway, A. Sharma, A. Hammad, S. Mehra
Journal: International Journal of Surgery (2016)
The Utility of Detection Populations of T-Lymphocytes, T-Killer Cells and Natural Killer Cells by CD2 Expression In White Blood Cell Differential Using Flow Cytometry
Authors: Ekaterina B. Rusanova, Margarita V. Gorchakova, Konstantin U. Slobodnyuk, Denis V. Cherednichenko, Yekaterina E. Zueva, Elena A. Sukhacheva, Ramon Simon-Lopez
Journal: Blood (2010)
Fluctuation Analysis of Peak Expiratory Flow and Its Association with Treatment Failure in Asthma
Authors: David A. Kaminsky, Lucy L. Wang, Jason H. T. Bates, Cindy Thamrin, David M. Shade, Anne E. Dixon, Robert A. Wise, Stephen Peters, Charles G. Irvin
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Temporal fluctuations have been demonstrated in lung function and asthma control, but the effect of controller therapy on these fluctuations is unknown.To determine if fluctuations in peak expiratory flow (PEF) are predictive of subsequent treatment failure and may be modified by controller therapy.We applied detrended fluctuation analysis to once-daily PEF data from 493 participants in the LOCCS (Leukotriene Modifier Corticosteroid or Corticosteroid-Salmeterol) trial of the American Lung Association Airways Clinical Research Centers. We evaluated the coefficient of variation of PEF (CVpef) and the scaling exponent α, reflecting self-similarity of PEF, in relation to treatment failure from the run-in period of open-label inhaled fluticasone, and the treatment periods for subjects randomized to (1) continued twice daily fluticasone (F), (2) once daily fluticasone plus salmeterol (F + S), or (3) once daily oral montelukast (M).The CVpef was higher in those with treatment failure in the F and F + S groups in the run-in phase, and all three groups in the treatment phase. α was similar between those with and without treatment failure in all three groups during the run-in phase but was higher among those with treatment failure in the F and F + S groups during the treatment phase. Participants in all three groups showed variable patterns of change in α leading up to treatment failure.We conclude that increased temporal self-similarity (α) of more variable lung function (CVpef) is associated with treatment failure, but the pattern of change in self-similarity leading up to treatment failure is variable across individuals.
THU0417 Serum Levels of GDF15 Are Elevated in Spondyloarthritis, and Negatively Linked with Bone Erosion
Authors: Y. Song, Y. Cui, H. Lin, G. Zhang, H. Zeng, Y. Zeng
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In order to assess disease activity and predict outcomes of patients with spondyloarthritis (SpA), it is necessary to discover useful serum biomarker reflecting inflammation, fat deposition, erosion and ankylosis [1]. GDF15 was previously fond related to inflammation [2] and worked as a protective factor in inflammatory pathology. In rheumatology arthritis patients, serum level of GDF15 could predict the presence of joint erosions [3]. <h3>Objectives</h3> The objective was to assess associations between GDF15 and radiographic features, including X-ray and MRI of the sacroiliac joint in SpA patients. <h3>Methods</h3> SpA was defined according to 2009 ASAS criteria. Sera from 53 patients with SpA and 18 healthy controls were measured GDF15 levels using ELISA. Inflammation was assessed by ESR, CRP and MRI of the SIJ, using the Spondyloarthritis Research Consortium of Canada (SPARCC) score and a method of dichotomy to assess fat deposition, bone erosion and ankylosis. Radiographs of the pelvis were scored by using the modified New York (mNY) score. <h3>Results</h3> Serum GDF15 levels were higher in SpA patients in comparison with controls (208.4 ± 173.7 vs 339.2 ± 295.0 pg/ml and P=0.005 Figure). Among SpA, patients who suffered from bone erosion on MRI had lower levels of GDF15 (423.4± 288.1 vs 284.3± 275.6 pg/ml and P=0.022).In addition, correlation analysis showed there was a negative correlation between serum GDF15 and bone erosion (r= -0.433, p=0.007) in SpA patients whose X-rays were 0-III according to mNY criteria. Moreover, GDF15 levels of those patients were related to CRP levels ((r=0.328, p=0.044). No significant correlations were found between SPARCC score, fat deposition and ankylosis and GDF15 levels, but CRP and ESR levels were significantly correlated with SPARCC score (r=0.291, p=0.036 and r=0.474, p=0.0004) in SpA. <h3>Conclusions</h3> Our study suggested that serum GDF15 levels were higher in SpA patients than healthy controls.GDF15 was correlated with CRP which was correlated with SPARCC score, suggesting GDF15 may not directly related to bone edema in SpA. GDF15 was negatively related to bone erosion, which may play a protective role in process of bone erosion. <h3>References</h3> Maksymowych W.P., Biomarkers in axial spondyloarthritis. Curr Opin Rheumatol, 2015. 27(4): p. 343–8. Lindahl B., The story of growth differentiation factor 15: another piece of the puzzle. Clin Chem, 2013. 59(11): p. 1550–2. Brown, D.A., et al., Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum, 2007. 56(3): p. 753–64. <h3>Disclosure of Interest</h3> None declared
Case 35-2016
Authors: Eunice L. Kwak, Theodore S. Hong, David G. Forcione, Avinash Kambadakone, Jochen K. Lennerz
Journal: New England Journal of Medicine (2016)

A 62-year-old man presented with metastatic esophageal adenocarcinoma. Two months earlier, imaging revealed a distal esophageal mass and enlarged lymph nodes; biopsy revealed adenocarcinoma that had metastasized to the lymph nodes. Management decisions were made.
PTH-114 Infection in Severe Alcoholic Hepatitis: Results from The Stopah Trial
Authors: S Atkinson, N Vergis, M Thursz
Journal: Gut (2016)

<h3>Introduction</h3> Severe alcoholic hepatitis (SAH; mDF ≥ 32) is often complicated by infection. In the recent trial STOPAH, prednisolone was associated with a doubling of the numbers of infections classified as serious adverse events (SAEs). We sought to identify the determinants of infection and the impact of infection on mortality. <h3>Methods</h3> Data regarding infection were collected weekly during admission and at all trial visits; SAE reports were included. Incident infection was defined as new infection occurring after treatment start. The follow-up period considered was 120 days. <h3>Results</h3> Data from 1093 cases were available. 127 patients were infected at baseline; this was not associated incident infection (p = 0.51) or 90 day mortality (p = 0.19). 308 patients developed an incident infection; 100 were reported as SAEs. As in other studies in SAH median time to infection was 13 days. Age (p = 0.015), WHO performance status (PS; p = 0.007), WBC (p = 0.002), INR (p = 0.023) and creatinine (p = 0.02) at baseline were associated with incident infection. On multivariate analysis PS (p = 0.02) and WBC (p = 0.00016) remained associated. DF (p = 0.011) and GAHS (p = 0.003) but not MELD (p = 0.41) associated with incident infection. Lille score was associated with incident infection after day 7 (p = 0.013). However, infection within 7 days was itself associated with Lille non-response (p = 0.008, OR 1.78 [95%CI 1.32–2.40]), independent of prednisolone treatment. Although infections classified as SAEs were more common in the prednisolone treated group (p = 0.001, OR 2.51 (95%CI 1.46–4.30). There was no association between prednisolone and all incident infections occurring during treatment (p = 0.88), but prednisolone was associated with infection in the post-treatment period (p = 0.023, OR 1.92 [95% CI, 1.10–3.35]). Incident infection was associated with 28 (p &lt; 0.001) and 120 day mortality (p = 0.001). This was independent of prednisolone therapy and Lille response. Prednisolone-treated Lille non-responders had a higher rate of incident infection at day 120 (49% vs 27%; p &lt; 0.0001). <h3>Conclusion</h3> In SAH incident infection is associated with mortality independently of early improvement in liver function measured by Lille. Very early onset of infection is associated with classification as a Lille non-responder. Thus in some instances Lille non-response may represent untreated infection not steroid treatment-failure. An association between prednisolone and post-treatment infection may explain the catch-up mortality after 28 days and fleeting benefit of prednisolone seen in STOPAH. <h3>Disclosure of Interest</h3> None Declared
AML with 11q23/MLL Abnormalities: A Survey of 146 Cases from French AML Intergroup.
Authors: Anne Banos, Antoine Jaquet, Herve Dombret, Anne Auvrignon, Nicole Dastugue, Sylvie Castaigne, Thierry Leblanc, Pierre Fenaux, Francoise Rigal-huguet, Francis Witz, Didier Blaise, Josy Reiffers, Guy Leverger, Jean-luc Harousseau, Gerard Socie, Denis Fiere, Bruno Lioure, Christian Bastard, Xavier Thomas, Thierry Lamy, Arnaud Pigneux
Journal: Blood (2006)
Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.
Authors: David M. Lucas, Syed-Rehan A. Hussain, Amy J. Johnson, Lisa L. Smith, Amy J. Wagner, Jamie M. Allison, Sara E. Guster, Thomas S. Lin, John C. Byrd, Mark W. Julian, Elliott D. Crouser, Michael R. Grever
Journal: Blood (2006)
Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study
Authors: Fabio Efficace, Gianluca Gaidano, Maria Teresa Voso, Giovanni Caocci, Massimo Breccia, Anna Angela Di Tucci, Reinhard Stauder, Dominik L.D. Selleslag, Susan Wood, Chonghua Wan, Grazia Sanpaolo, Monia Lunghi, Lodovico Balducci, Francesco Cottone, Marco Vignetti, Franco Mandelli
Journal: Blood (2010)
Сторінки історії надання медичної допомоги на Катеринославщині — Дніпропетровщині
Authors: M.P. Chaban, Z.I. Shevtsova, V.V. Gaponov
Journal: GASTROENTEROLOGY (2016)

Стаття присвячена благодійній діяльності княгині Наталії Черкаської (уродженої Катеринич) наприкінці ХІХ століття на Катеринославщині — Дніпропетровщині. Н.І. Черкаська відкрила лікарню й школу в селі Личковому. Вона була попечителькою Перещепинського приймального покою, почесною наглядачкою Катеринославського єпархіального жіночого училища. Надані відомості про перебування представників роду видатного вченого І.І. Мечникова на Катеринославщині.
Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing
Authors: Pauline Robbe, Romain Guièze, Ruth M Clifford, Sophie de Guibert, Adele Timbs, Marie-Sarah Dilhuydy, Maite Cabes, Loic Ysebaert, Adam Burns, Florence Nguyen-Khac, Frederic Davi, Lauren Veronese, Patricia Combes, Magali Le Garff-Tavernier, Veronique Leblond, Hélène Merle-Béral, Reem Alsolami, Susanne Weller, Angela Hamblin, Joanne Mason, Andrew R Pettitt, Peter Hillmen, Jenny Taylor, Samantha JL Knight, Anna Schuh, Olivier Tournilhac
Journal: Blood (2014)
CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment.
Authors: Mariela Sivina, Elena Hartmann, Diana Krupnik, Ruth LaPushin, Michael Keating, Thomas J. Kipps, Andreas Rosenwald, William G Wierda, Jan A. Burger
Journal: Blood (2009)